Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Combined With Camrelizumab and Chemo in Recurrent ESCC
NCT06010212Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Aug 2023
- Primary completion
- Aug 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of fruquintinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Jiangsu Provincial People's Hospital. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06010212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010212.